Harrow, Inc. (HROW)
38.56
+1.59
(+4.30%)
USD |
NASDAQ |
Sep 02, 12:50
Harrow Research and Development Expense (Annual) : 12.85M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 12.85M |
| December 31, 2024 | 12.95M |
| December 31, 2023 | 6.883M |
| December 31, 2022 | 3.151M |
| December 31, 2021 | 11.18M |
| December 31, 2020 | 3.072M |
| December 31, 2019 | 2.083M |
| December 31, 2018 | 0.825M |
| December 31, 2017 | 0.413M |
| December 31, 2016 | 0.739M |
| December 31, 2015 | 0.332M |
| Date | Value |
|---|---|
| December 31, 2014 | 0.2367M |
| December 31, 2013 | 1.616M |
| December 31, 2012 | 1.298M |
| December 31, 2011 | 0.1116M |
| December 31, 2010 | 0.1946M |
| December 31, 2009 | 2.966M |
| December 31, 2008 | 1.991M |
| December 31, 2007 | 1.833M |
| December 31, 2006 | 0.00 |
| December 31, 2005 | 0.00 |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Viatris, Inc. | 952.50M |
| Zevra Therapeutics, Inc. | 12.55M |
| Indivior Pharmaceuticals, Inc. | 80.00M |
| Liquidia Corp. | 38.45M |
| 60 Degrees Pharmaceuticals, Inc. | 2.106M |